中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

酒精性肝病合并肌肉减少症的研究进展

王倩 常春艳 杨松

王倩,常春艳,杨松. 酒精性肝病合并肌肉减少症的研究进展[J]. 临床肝胆病杂志, 2021, 37(8): 1943-1947. DOI: 10.3969/j.issn.1001-5256.2021.08.043
引用本文: 王倩,常春艳,杨松. 酒精性肝病合并肌肉减少症的研究进展[J]. 临床肝胆病杂志, 2021, 37(8): 1943-1947. DOI: 10.3969/j.issn.1001-5256.2021.08.043
WANG Q, CHANG CY, YANG S. Research advances in alcoholic liver disease with sarcopenia[J]. J Clin Hepatol, 2021, 37(8): 1943-1947. DOI: 10.3969/j.issn.1001-5256.2021.08.043
Citation: WANG Q, CHANG CY, YANG S. Research advances in alcoholic liver disease with sarcopenia[J]. J Clin Hepatol, 2021, 37(8): 1943-1947. DOI: 10.3969/j.issn.1001-5256.2021.08.043

酒精性肝病合并肌肉减少症的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.08.043
基金项目: 

国家科技重大专项 2017ZX10202202

国家科技重大专项 2018ZX10715-005

青海省高端创新人才千人计划 2019-24

中国肝炎防治基金会天晴肝病研究基金 TQGB20210050

详细信息
    通讯作者:

    杨松,sduyangsong@163.com

  • 中图分类号: R575.5

Research advances in alcoholic liver disease with sarcopenia

Funds: 

National Science and Technology Major Project 2017ZX10202202

National Science and Technology Major Project 2018ZX10715-005

Qinghai Provincial High-end and Innovative 1000 Talents Plan 2019-24

Chinese Foundation for Hepatitis Prevention and Control-TianQing Liver Disease Research Fund TQGB20210050

  • 摘要: 酒精性肝病是影响我国人民健康的主要肝脏疾病之一, 约有60%的酒精性肝病患者合并肌肉减少症。就酒精性肝病发生肌肉减少症的机制而言,除了肝病患者存在食欲下降、营养物质摄入不足、消化吸收障碍、体力活动减少、血氨升高等因素外,酒精及其代谢产物还可作用于多个信号通路影响骨骼肌蛋白合成,促进骨骼肌细胞自噬。酒精性肝病患者合并肌肉减少症发生肝性脑病、肝癌等不良预后风险增加。针对酒精性肝病患者肌肉减少症的干预措施有待深入研究。

     

  • 表  1  2019年AWGS肌少症的诊断标准及临界值

    评价维度 评价指标 临界值
    男性 女性
    肌力 握力 <28 kg <18 kg
    体能表现 6米步行速度 <1.0 m/s <1.0 m/s
    FTSTS ≥12 s ≥12 s
    SPPB ≤9分 ≤9分
    肌量 ASM(DXA测量) <7.0 kg/m2 <5.4 kg/m2
    ASM(BIA测量) <7.0 kg/m2 <5.7 kg/m2
    诊断标准:可能肌少症,肌力下降和/或体能减退;确诊肌少症,肌力下降和/或体能减退+肌量减少;严重肌少症,肌力下降+体能减退+肌量减少
    注:FTSTS,5次坐立试验;SPPB,简易机体功能评估法;ASM,四肢肌量;BIA,生物电阻抗测量分析;DXA,双能X线吸收测量。
    下载: 导出CSV
  • [1] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.007.
    [2] CRUZ-JENTOFT AJ, BAHAT G, BAUER J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 601. DOI: 10.1093/ageing/afz046.
    [3] CHEN LK, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 Consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012.
    [4] TRAUB J, BERGHEIM I, EIBISBERGER M, et al. Sarcopenia and liver cirrhosis-comparison of the European Working Group on sarcopenia criteria 2010 and 2019[J]. Nutrients, 2020, 12(2): 547. DOI: 10.3390/nu12020547.
    [5] HSU CS, KAO JH. Sarcopenia and chronic liver diseases[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(12): 1229-1244. DOI: 10.1080/17474124.2018.1534586.
    [6] European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [7] ITOH S, SHIRABE K, YOSHIZUMI T, et al. Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience[J]. Hepatol Res, 2016, 46(4): 292-297. DOI: 10.1111/hepr.12537.
    [8] SCHWEITZER L, GEISLER C, POURHASSAN M, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults?[J]. Am J Clin Nutr, 2015, 102(1): 58-65. DOI: 10.3945/ajcn.115.111203.
    [9] TAGUCHI S, AKAMATSU N, NAKAGAWA T, et al. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma[J]. Clin Genitourin Cancer, 2016, 14(3): 237-243. DOI: 10.1016/j.clgc.2015.07.015.
    [10] SCHWEITZER L, GEISLER C, POURHASSAN M, et al. Estimation of skeletal muscle mass and visceral adipose tissue volume by a single magnetic resonance imaging slice in healthy elderly adults[J]. J Nutr, 2016, 146(10): 2143-2148. DOI: 10.3945/jn.116.236844.
    [11] PRADO CM, LIEFFERS JR, MCCARGAR LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study[J]. Lancet Oncol, 2008, 9(7): 629-635. DOI: 10.1016/S1470-2045(08)70153-0.
    [12] CAREY EJ, LAI JC, WANG CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5): 625-633. DOI: 10.1002/lt.24750.
    [13] ROMAGNA ES, APPEL-DA-SILVA MC, SUWA E, et al. Muscle depletion in cirrhotic patients assessed using computed tomography: A cross-sectional study[J]. Sao Paulo Med J, 2020, 138(2): 152-157. DOI: 10.1590/1516-3180.2019.0436.R1.19122019.
    [14] IMAI K, TAKAI K, WATANABE S, et al. Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: The role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume[J]. Nutrients, 2017, 9(10): 1054. DOI: 10.3390/nu9101054.
    [15] SHI ZW. Association of L3 skeletal muscle index and prognosis in patients with liver cirrhosis[D]. Shanghai: The Naval Medical University of the People's Liberation Army, 2019.

    石志文. L3骨骼肌指数评估肝硬化患者预后的相关研究[D]. 上海: 中国人民解放军海军军医大学, 2019.
    [16] GU DH, KIM MY, SEO YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis[J]. Clin Mol Hepatol, 2018, 24(3): 319-330. DOI: 10.3350/cmh.2017.0077.
    [17] KIM G, KANG SH, KIM MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(10): e0186990. DOI: 10.1371/journal.pone.0186990.
    [18] DASARATHY S. Nutrition and alcoholic liver disease: Effects of alcoholism on nutrition, effects of nutrition on alcoholic liver disease, and nutritional therapies for alcoholic liver disease[J]. Clin Liver Dis, 2016, 20(3): 535-550. DOI: 10.1016/j.cld.2016.02.010.
    [19] DASARATHY J, MCCULLOUGH AJ, DASARATHY S. Sarcopenia in alcoholic liver disease: Clinical and molecular advances[J]. Alcohol Clin Exp Res, 2017, 41(8): 1419-1431. DOI: 10.1111/acer.13425.
    [20] STEINER JL, LANG CH. Dysregulation of skeletal muscle protein metabolism by alcohol[J]. Am J Physiol Endocrinol Metab, 2015, 308(9): e699-e712. DOI: 10.1152/ajpendo.00006.2015.
    [21] WELCH N, DASARATHY J, RUNKANA A, et al. Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease[J]. Liver Int, 2020, 40(5): 1178-1188. DOI: 10.1111/liv.14358.
    [22] DASARATHY S, MERLI M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol, 2016, 65(6): 1232-1244. DOI: 10.1016/j.jhep.2016.07.040.
    [23] DAVULURI G, WELCH N, SEKAR J, et al. Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease[J]. Hepatology, 2021, 73(5): 1892-1908. DOI: 10.1002/hep.31524.
    [24] KANT S, DAVULURI G, ALCHIRAZI KA, et al. Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations[J]. J Biol Chem, 2019, 294(18): 7231-7244. DOI: 10.1074/jbc.RA118.005411.
    [25] KUMAR A, DAVULURI G, WELCH N, et al. Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy[J]. Free Radic Biol Med, 2019, 145: 284-299. DOI: 10.1016/j.freeradbiomed.2019.09.031.
    [26] ADLER K, MOLINA PE, SIMON L. Epigenomic mechanisms of alcohol-induced impaired differentiation of skeletal muscle stem cells; role of Class ⅡA histone deacetylases[J]. Physiol Genomics, 2019, 51(9): 471-479. DOI: 10.1152/physiolgenomics.00043.2019.
    [27] HANAI T, SHIRAKI M, NISHIMURA K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis[J]. Nutrition, 2015, 31(1): 193-199. DOI: 10.1016/j.nut.2014.07.005.
    [28] XIAO HJ, YE Q, ZHANG M, et al. Risk factors of cirrhosis combined with sarcopenia and their impact on clinical outcomes[J]. Chin J Hepatol, 2020, 28(1): 53-57. DOI: 10.3760/cma.j.issn.1007-3418.2020.01.013.

    肖慧娟, 叶青, 张明, 等. 肝硬化合并肌肉减少症的危险因素及其对临床结局的影响[J]. 中华肝脏病杂志, 2020, 28(1): 53-57. DOI: 10.3760/cma.j.issn.1007-3418.2020.01.013.
    [29] MONTANO-LOZA AJ, MEZA-JUNCO J, PRADO CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2012, 10(2): 166-173. DOI: 10.1016/j.cgh.2011.08.028.
    [30] WIJARNPREECHA K, WERLANG M, PANJAWATANAN P, et al. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2020, 19(3): 245-250. DOI: 10.1016/j.aohep.2019.06.007.
    [31] BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
    [32] CHANG KV, CHEN JD, WU WT, et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis[J]. J Formos Med Assoc, 2019, 118(4): 833-842. DOI: 10.1016/j.jfma.2018.09.011.
    [33] FOZOUNI L, WANG CW, LAI JC. Sex differences in the association between frailty and sarcopenia in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2019, 10(12): e00102. DOI: 10.14309/ctg.0000000000000102.
    [34] NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [35] FENG Z, ZHAO H, JIANG Y, et al. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis[J]. Clin Nutr, 2020, 39(10): 3132-3139. DOI: 10.1016/j.clnu.2020.01.021.
    [36] KUO SZ, AHMAD M, DUNN MA, et al. Sarcopenia predicts post-transplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation[J]. Transplantation, 2019, 103(11): 2312-2317. DOI: 10.1097/TP.0000000000002741.
    [37] FUJIWARA N, NAKAGAWA H, KUDO Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma[J]. J Hepatol, 2015, 63(1): 131-140. DOI: 10.1016/j.jhep.2015.02.031.
    [38] SALMAN MA, OMAR H, MIKHAIL H, et al. Sarcopenia increases 1-year mortality after surgical resection of hepatocellular carcinoma[J]. ANZ J Surg, 2020, 90(5): 781-785. DOI: 10.1111/ans.15647.
    [39] TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18(10): 1209-1216. DOI: 10.1002/lt.23495.
    [40] AL-AZZAWI Y, ALBO B, FASULLO M, et al. Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis[J]. Eur J Gastroenterol Hepatol, 2020, 32(6): 733-738. DOI: 10.1097/MEG.0000000000001583.
    [41] FIALLA AD, ISRAELSEN M, HAMBERG O, et al. Nutritional therapy in cirrhosis or alcoholic hepatitis: A systematic review and meta-analysis[J]. Liver Int, 2015, 35(9): 2072-2078. DOI: 10.1111/liv.12798.
    [42] PURI P, THURSZ M. Intensive enteral nutrition in alcoholic hepatitis: More food for thought[J]. Gastroenterology, 2016, 150(4): 803-805. DOI: 10.1053/j.gastro.2016.02.061.
    [43] TSIEN CD, MCCULLOUGH AJ, DASARATHY S. Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis[J]. J Gastroenterol Hepatol, 2012, 27(3): 430-441. DOI: 10.1111/j.1440-1746.2011.06951.x.
    [44] ANAND AC. Nutrition and muscle in cirrhosis[J]. J Clin Exp Hepatol, 2017, 7(4): 340-357. DOI: 10.1016/j.jceh.2017.11.001.
    [45] DAVULURI G, KROKOWSKI D, GUAN BJ, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis[J]. J Hepatol, 2016, 65(5): 929-937. DOI: 10.1016/j.jhep.2016.06.004.
    [46] TSIEN C, DAVULURI G, SINGH D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology, 2015, 61(6): 2018-2029. DOI: 10.1002/hep.27717.
    [47] LI JH, YAO J, YUAN LL. Association between sarcopenia and hepatic encephalopathy and advances in diagnosis and treatment[J]. J Clin Hepatol, 2020, 36(6): 1412-1414. DOI: 10.3969/j.issn.1001-5256.2020.06.049.

    李建宏, 姚佳, 原丽莉. 肌肉减少症与肝性脑病的关系及诊疗进展[J]. 临床肝胆病杂志, 2020, 36(6): 1412-1414. DOI: 10.3969/j.issn.1001-5256.2020.06.049.
    [48] DIDSBURY M, MCGEE RG, TONG A, et al. Exercise training in solid organ transplant recipients: A systematic review and meta-analysis[J]. Transplantation, 2013, 95(5): 679-687. DOI: 10.1097/TP.0b013e31827a3d3e.
    [49] NASEER M, TURSE EP, SYED A, et al. Interventions to improve sarcopenia in cirrhosis: A systematic review[J]. World J Clin Cases, 2019, 7(2): 156-170. DOI: 10.12998/wjcc.v7.i2.156.
    [50] HIRAOKA A, MICHITAKA K, KIGUCHI D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2017, 29(12): 1416-1423. DOI: 10.1097/MEG.0000000000000986.
    [51] ROMÁN E, TORRADES MT, NADAL MJ, et al. Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis[J]. Dig Dis Sci, 2014, 59(8): 1966-1975. DOI: 10.1007/s10620-014-3086-6.
    [52] WANG BY. Importance of the clinical research on alcoholic hepatitis[J]. J Clin Hepatol, 2019, 35(3): 469-471. DOI: 10.3969/j.issn.1001-5256.2019.03.002.

    王炳元. 重视酒精性肝炎的临床研究[J]. 临床肝胆病杂志, 2019, 35(3): 469-471. DOI: 10.3969/j.issn.1001-5256.2019.03.002.
    [53] SINCLAIR M, GROSSMANN M, HOERMANN R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial[J]. J Hepatol, 2016, 65(5): 906-913. DOI: 10.1016/j.jhep.2016.06.007.
    [54] KUMAR A, DAVULURI G, SILVA R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology, 2017, 65(6): 2045-2058. DOI: 10.1002/hep.29107.
    [55] KWAK JY, KWON KS. Pharmacological interventions for treatment of sarcopenia: Current status of drug development for sarcopenia[J]. Ann Geriatr Med Res, 2019, 23(3): 98-104. DOI: 10.4235/agmr.19.0028.
  • 加载中
表(1)
计量
  • 文章访问数:  49
  • HTML全文浏览量:  18
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-21
  • 修回日期:  2021-02-05
  • 刊出日期:  2021-08-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回